ArticleACS synthetic biology2013
Antimicrobial peptides targeting Gram-negative pathogens, produced and delivered by lactic acid bacteria.
Article in ACS synthetic biology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 82 citations in OpenAlex.
- Danggui Buxue Decoction AttenuatesVeterinary sciences · 2026Article
- Protective Effects of RecombinantAnimals : an open access journal from MDPI · 2026Article
- Probiotics and Postbiotics Derived from Saline/Marine Plant-Based Feedstocks.Probiotics and antimicrobial proteins · 2026Review
- Direct-fed Microbials (DFM) and Poultry Genomics: A Synergistic Approach to Sustainable Antibiotic Free Farming.Probiotics and antimicrobial proteins · 2026Review
- Precision Antimicrobial Therapy Against Fusobacterium nucleatum Using Bioengineered Probiotics Expressing Guided Antimicrobial Peptides (gAMPs).Microbial biotechnology · 2025Article
- Being a better version of yourself: genetically engineered probiotic bacteria as host defense enhancers in the control of intestinal pathogens.Gut microbes · 2025Review
- Engineered Mycoplasma pneumoniae targeting dual-species bacterial biofilms: a novel strategy against infections.NPJ biofilms and microbiomes · 2025Article
- Forging a New Frontier: Antimicrobial Peptides and Nanotechnology Converging to Conquer Gastrointestinal Pathogens.Small (Weinheim an der Bergstrasse, Germany) · 2025Review
- Novel Genetically Engineered Probiotics for Targeted Elimination ofBiomedicines · 2023Article
- Bacillus Species as Direct-Fed Microbial Antibiotic Alternatives for Monogastric Production.Probiotics and antimicrobial proteins · 2023Review
- Acyldepsipeptide Analogues: A Future Generation Antibiotics for Tuberculosis Treatment.Pharmaceutics · 2022Review
- Gastrointestinal Microbiota and Their Manipulation for Improved Growth and Performance in Chickens.Foods (Basel, Switzerland) · 2022Review
- Detection of antibacterial activity of lactic acid bacteria, isolated from Sumba mare's milk, against Bacillus cereus, Staphylococcus aureus, and Escherichia coli.Journal of advanced veterinary and animal research · 2022Article
- Probiotic engineering strategies for the heterologous production of antimicrobial peptides.Advanced drug delivery reviews · 2021Review
- Role of probiotics in prevention and treatment of enteric infections: a comprehensive review.3 Biotech · 2021Review
- Large-Peptide Permeation Through a Membrane Channel: Understanding Protamine Translocation Through CymA from Klebsiella Oxytoca*.Angewandte Chemie (International ed. in English) · 2021Article
- Targeted Therapeutic Strategies in the Battle Against Pathogenic Bacteria.Frontiers in pharmacology · 2021Review
- Mining and Statistical Modeling of Natural and Variant Class IIa Bacteriocins Elucidate Activity and Selectivity Profiles across Species.Applied and environmental microbiology · 2020Article
- Using Colistin as a Trojan Horse: Inactivation of Gram-Negative Bacteria with Chlorophyllin.Antibiotics (Basel, Switzerland) · 2019Article
- Engineered probiotic Escherichia coli can eliminate and prevent Pseudomonas aeruginosa gut infection in animal models.Nature communications · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
We present results of tests with recombinant Lactococcus lactis that produce and secrete heterologous antimicrobial peptides with activity against Gram-negative pathogenic Escherichia coli and Salmonella . In an initial screening, the activities of numerous candidate antimicrobial peptides, made by solid state synthesis, were assessed against several indicator pathogenic E. coli and Salmonella strains. Peptides A3APO and Alyteserin were selected as top performers based on high antimicrobial activity against the pathogens tested and on significantly lower antimicrobial activity against L. lactis . Expression cassettes containing the signal peptide of the protein Usp45 fused to the codon-optimized sequence of mature A3APO and Alyteserin were cloned under the control of a nisin-inducible promoter PnisA and transformed into L. lactis IL1403. The resulting recombinant strains were induced to express and secrete both peptides. A3APO- and Alyteserin-containing supernatants from these recombinant L. lactis inhibited the growth of pathogenic E. coli and Salmonella by up to 20-fold, while maintaining the host's viability. This system may serve as a model for the production and delivery of antimicrobial peptides by lactic acid bacteria to target Gram-negative pathogenic bacteria populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.